These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Takano R; Misu T; Takahashi T; Sato S; Fujihara K; Itoyama Y Neurology; 2010 Jul; 75(3):208-16. PubMed ID: 20644148 [TBL] [Abstract][Full Text] [Related]
11. Serum and cerebrospinal fluid concentrations of homoarginine, arginine, asymmetric and symmetric dimethylarginine, nitrite and nitrate in patients with multiple sclerosis and neuromyelitis optica. Haghikia A; Kayacelebi AA; Beckmann B; Hanff E; Gold R; Haghikia A; Tsikas D Amino Acids; 2015 Sep; 47(9):1837-45. PubMed ID: 26055922 [TBL] [Abstract][Full Text] [Related]
12. Some markers of neuronal damage in cerebrospinal fluid of multiple sclerosis patients in relapse. Mitosek-Szewczyk K; Gordon-Krajcer W; Flis D; Stelmasiak Z Folia Neuropathol; 2011; 49(3):191-6. PubMed ID: 22101952 [TBL] [Abstract][Full Text] [Related]
13. Serum and cerebrospinal fluid S100B, neuron-specific enolase, and total tau protein in acute encephalopathy with biphasic seizures and late reduced diffusion: a diagnostic validity. Shiihara T; Miyake T; Izumi S; Watanabe M; Kamayachi K; Kodama K; Nabetani M; Ikemiyagi M; Yamaguchi Y; Sawaura N Pediatr Int; 2012 Feb; 54(1):52-5. PubMed ID: 21883688 [TBL] [Abstract][Full Text] [Related]
14. The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis. Bartosik-Psujek H; Stelmasiak Z J Neural Transm (Vienna); 2006 Mar; 113(3):339-45. PubMed ID: 15997419 [TBL] [Abstract][Full Text] [Related]
15. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Malmeström C; Haghighi S; Rosengren L; Andersen O; Lycke J Neurology; 2003 Dec; 61(12):1720-5. PubMed ID: 14694036 [TBL] [Abstract][Full Text] [Related]
16. Raised cerebrospinal fluid nitrite and nitrate levels in patients with multiple sclerosis: no correlation with disease activity. Drulović J; Dujmović I; Mesaros S; Samardzić T; Maksimović D; Stojsavljević N; Lević Z; Mostarica Stojokvić M Mult Scler; 2001 Feb; 7(1):19-22. PubMed ID: 11321188 [TBL] [Abstract][Full Text] [Related]
17. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Brettschneider J; Petzold A; Junker A; Tumani H Mult Scler; 2006 Apr; 12(2):143-8. PubMed ID: 16629417 [TBL] [Abstract][Full Text] [Related]
18. Lipopolysaccharide modulates astrocytic S100B secretion: a study in cerebrospinal fluid and astrocyte cultures from rats. Guerra MC; Tortorelli LS; Galland F; Da Ré C; Negri E; Engelke DS; Rodrigues L; Leite MC; Gonçalves CA J Neuroinflammation; 2011 Oct; 8():128. PubMed ID: 21970823 [TBL] [Abstract][Full Text] [Related]
19. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Guimarães I; Cardoso MI; Sá MJ Mult Scler; 2006 Jun; 12(3):354-6. PubMed ID: 16764350 [TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid from patients with neurodegenerative and neuroinflammatory diseases: no evidence for rat glial activation in vitro. Wilms H; Rosenstiel P; Sievers J; Deuschl G; Lucius R Neurosci Lett; 2001 Nov; 314(3):107-10. PubMed ID: 11704295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]